Animab
Animab is developing antibodies that can be administered orally to animals.
Animab has raised €10M across 1 funding round from 6 investors, most recently a Series A round in Nov 2022. Based in Ghent, Belgium; active in Agritech. Data as of 28 Oct 2026.
Ghent, Belgiumwww.animab.com ↗
Total raised
€10M
€10,000,000
Funding rounds
1
Investors
6
distinct backers
Active since
2022-11
latest 2022-11
Funding by year
EUR raised per yearAnimab — funding by year — interactive chart.
Data table
| Animab — funding by year | |
|---|---|
| 2022 | €10M |
Signals
High confidenceRaise-next likelihood8
base rate 44% for Series A
- ▼ Past typical raise window
- ▼ Low backer re-investment
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-11-09 | Series A | €10M | AIF,PMV,Qbic III,Seventure Partners,V-Bio Ventures,VIB | View deal → |
Related news
- Gentse biotech start-up trekt 10 miljoen euro kapitaal aanbloovi.be · 2022-11
Similar companies
same sector or countryGlobal coverage: FundingData